Deepull Diagnostics SL raised €50 million (US$56.93 million) in an oversubscribed series C financing round to complete clinical validation studies of its UllCORE diagnostic system for direct-from-blood rapid pathogen detection.
Venture Capital firm Asabys Partners closed its second fund, Sabadell Asabys Health Innovation Investments II, with total commitments of €180 million ($200 million). The funds will go towards 12 to 15 companies developing health care solutions across the medical device, digital health and biopharma fields.
Another company has entered the fray in the eternal battle between humans and bacteria. Day Zero Diagnostics Inc. aims to produce whole genome sequencing-based diagnostic technologies that quickly identify the species and antibiotic resistance profile of bacterial pathogens from a blood sample. In a vote of confidence that the company is on the right track, the global non-profit Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) awarded Day Zero another $8.2 million. The latest funding pushes Day Zero’s awards from CARB-X over $16 million.
